newsfilter
← Latest News
ACCESS Newswire·

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

  • Sunshine Biopharma Inc. (NASDAQ: SBFM) received approval for generic 2mg Dienogest tablets in the Canadian market as the generic equivalent of Visanne®.
  • Dienogest functions via progesterone receptor binding, local anti-inflammatory actions, & mild hormone suppression to reduce endometriosis pain by shrinking abnormal tissue growth.
  • The global Dienogest market was valued at $2.8 billion in 2025 & is projected to reach $5.2 billion by 2034 with a CAGR of 7.8%.
  • The Canadian pharmaceutical market represents approximately 2.1% of the global total & ranks as the sixth largest worldwide.
  • Sunshine Biopharma utilizes its subsidiary Nora Pharma Inc. for distribution & anticipates shipping the new medication to Canadian pharmacies by the end of 2026.
  • CEO Dr. Steve Slilaty stated the approval strengthens the company's position in the women's health market.
  • Sunshine Biopharma currently markets 60 generic prescription drugs in Canada with 12 additional drugs scheduled for launch in 2026.
  • The company is conducting proprietary drug development programs for liver cancer (K1.1 mRNA) & SARS Coronavirus infections (PLpro protease inhibitor).